Merck & Co., Inc. (TSX:MRK)
Canada · Delayed Price · Currency is CAD | Market Cap | 524.51B +78.0% |
| Revenue (ttm) | 94.53B +4.6% |
| Net Income | 4.51B -80.7% |
| EPS | 1.81 -80.4% |
| Shares Out | n/a |
| PE Ratio | 116.40 |
| Forward PE | 17.58 |
| Dividend | 0.77 (2.24%) |
| Ex-Dividend Date | Sep 15, 2026 |
| Volume | 1,900 |
| Open | 33.54 |
| Previous Close | 34.10 |
| Day's Range | 33.30 - 33.81 |
| 52-Week Range | 17.66 - 34.90 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock produ... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial numbers in USD Financial StatementsNews
Explainer: How the Merck/Moderna cancer vaccine works and possible barriers to wide use
The personalized cancer vaccine being developed by Moderna and Merck has boosted hopes that mRNA technology could open up a new avenue of treatment, but the available evidence is still limited.
What Happens if Moderna's Cancer Vaccine Works
Moderna and Merck's personalized cancer vaccine could transform cancer treatment and create a multibillion-dollar market, but investors may already be pricing in much of its potential.
Merck price target raised to $170 from $145 at Argus
Argus analyst Jasper Hellweg raised the firm’s price target on Merck (MRK) to $170 from $145 and keeps a Buy rating on the shares. From a portfolio standpoint, the company…
Merck price target raised to $180 from $155 at Wolfe Research
Wolfe Research analyst Alexandria Hammond raised the firm’s price target on Merck (MRK) to $180 from $155 and keeps an Outperform rating on the shares. The firm sees the positive…
Emily Field: Large pharma companies are going to continue looking at biotech
Emily Field, Head of U.S. Biopharma Equity Research at Barclays, says biotech is gaining momentum as M&A returns, capital markets reopen and breakthroughs in cancer vaccines fuel investor interest.
Why Is Merck Stock Still An Undervalued Mega-Cap In Pharma?
This article was written by Doug Nathman, with research by his team at Trefis.
Merck price target raised to $160 from $140 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Merck (MRK) to $160 from $140 and keeps a Buy rating on the shares. Merck’s shares surged after positive Phase 3 melanoma…
Merck Stock (MRK) Is a Strong Buy as 3 Top Wall Street Analysts Hike Price Targets
Merck & Co. ($MRK), a U.S. pharmaceutical firm, got a major boost on Thursday, August 20, after investment banks Morgan Stanley ($MS), UBS ($UBS) and Goldman Sachs ($GS) raised their…
Moderna is paring back gains, but Merck stock remains a buy
Moderna (MRNA) shares are paring back some of their recent gains on Thursday morning – but a Morgan Stanley analyst believes Merck (MRK) stock remains a buy following blockbuster cancer drug trial res...
Thursday's First Moves: Analysts Mixed on MRNA & MRK Rally, AAP & DE Earnings
Diane King Hall discusses the sharp sell-off in Advance Auto Parts (AAP) as the guidance shows strong headwinds. Deere (DE) offered plenty of strength in its earnings as construction revenues rise.
Moderna Stock Rockets Higher After Positive Cancer Vaccine Trial Data
Moderna and Merck delivered positive news about their personalized skin-cancer vaccine Wednesday. Investors bought their shares in droves.
Merck price target raised to $170 from $142 at BMO Capital
BMO Capital raised the firm’s price target on Merck (MRK) to $170 from $142 and keeps an Outperform rating on the shares. The company’s success in INTerpath-001 provides positive opportunity…
Moderna Stock (MRNA) Forecast: BofA Upgrades Rating on Cancer Vaccine Update, Goldman Raises Price Target
Moderna ($MRNA) stock rallied 177% on Wednesday after a cancer vaccine from the biotech company and Merck ($MRK) showed positive initial results in its first-ever late-stage trial. Reacting to the fav...
Merck price target raised to $175 from $145 at UBS
UBS raised the firm’s price target on Merck (MRK) to $175 from $145 and keeps a Buy rating on the shares. Moderna (MRNA) and Merck surged 176% and 12%, respectively,…
RBC downgrades Merck on ‘unprecedented valuation’ after vaccine data
RBC Capital analyst Trung Huynh downgraded Merck (MRK) to Sector Perform from Outperform with a price target of $150, up from $142. Merck’s cancer vaccine data exceeded expectations as its…
Merck price target raised to $166 from $141 at BofA
BofA raised the firm’s price target on Merck (MRK) to $166 from $141 and keeps a Buy rating on the shares. Merck’s positive Phase 3 melanoma data strengthen confidence in…
Moderna, Merck breakthrough could usher in wave of cancer vaccines
Merck and Moderna's success with a personalized cancer vaccine designed to keep melanoma at bay opens a new avenue of treatment that doctors hope will work against many types of tumors.
Merck, Moderna Stocks Soar After Melanoma Trial Success
Shares of Moderna and Merck soared on Wednesday morning after a study showed that a vaccine they produced had promising results when it comes to fighting skin cancer. A late-stage trial showed that th...
VIEW Moderna-Merck melanoma vaccine data boosts outlook, but analysts await full results
Moderna's personalized mRNA cancer therapy, developed with Merck , reduced the risk of melanoma recurrence and spread when used in combination with the U.S. drugmaker's blockbuster treatment Keytruda...
Merck, Moderna Melanoma Vaccine Study Succeeds
Merck and Moderna announced positive results from a large late-stage trial of their personalized mRNA cancer vaccine, which significantly reduced the recurrence of melanoma, the deadliest form of skin...
U.S. Treasury Boosts Debt Buybacks, UAE Cuts Off Iran, MRNA & MRK Melanoma Trial Results
The U.S. Treasury is "at least" doubling debt buybacks for longer-dated nominal coupon securities, causing a surge in fixed income activity after yields hit highs not seen in years. Kevin Hincks expla...
'An increased ability to disease-free': Moderna CEO & Merck's Dr. Li on skin cancel vaccine trial
Stephane Bancel, Moderna CEO, and Dr. Dean Li, Merck Research Laboratories president, join 'Squawk Box' to discuss details of an experimental personalized cancer vaccine that showed positive initial r...
Moderna, Merck, La-Z-Boy, SK Hynix, and More Stocks That Explain Today's Market
Stock markets are waited on minutes of the Fed's most recent monetary policy meeting for any clues about the forward path on interest rates.
Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial
Merck and Moderna said on Wednesday a study of a personalized mRNA vaccine combined with the immunotherapy drug Keytruda reduced melanoma skin cancer recurrence and spread compared with Keytruda alo...
Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial
An experimental personalized cancer vaccine from Merck and Moderna showed positive initial results in its first-ever late-stage trial. The combination regimen met the main study goal of significantly ...